JP2021535140A5 - - Google Patents
Info
- Publication number
- JP2021535140A5 JP2021535140A5 JP2021510639A JP2021510639A JP2021535140A5 JP 2021535140 A5 JP2021535140 A5 JP 2021535140A5 JP 2021510639 A JP2021510639 A JP 2021510639A JP 2021510639 A JP2021510639 A JP 2021510639A JP 2021535140 A5 JP2021535140 A5 JP 2021535140A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- naturally
- antibody fragment
- molecule
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025050991A JP2025098156A (ja) | 2018-08-28 | 2025-03-26 | 抗ｃｄ３抗体葉酸生物複合体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862723793P | 2018-08-28 | 2018-08-28 | |
| US62/723,793 | 2018-08-28 | ||
| PCT/US2019/048677 WO2020047176A1 (en) | 2018-08-28 | 2019-08-28 | Anti-cd3 antibody folate bioconjugates and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050991A Division JP2025098156A (ja) | 2018-08-28 | 2025-03-26 | 抗ｃｄ３抗体葉酸生物複合体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535140A JP2021535140A (ja) | 2021-12-16 |
| JP2021535140A5 true JP2021535140A5 (enExample) | 2022-09-06 |
| JP7759805B2 JP7759805B2 (ja) | 2025-10-24 |
Family
ID=68051890
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510639A Active JP7759805B2 (ja) | 2018-08-28 | 2019-08-28 | 抗ｃｄ３抗体葉酸生物複合体およびその使用 |
| JP2025050991A Pending JP2025098156A (ja) | 2018-08-28 | 2025-03-26 | 抗ｃｄ３抗体葉酸生物複合体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050991A Pending JP2025098156A (ja) | 2018-08-28 | 2025-03-26 | 抗ｃｄ３抗体葉酸生物複合体およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12377294B2 (enExample) |
| EP (1) | EP3844188A1 (enExample) |
| JP (2) | JP7759805B2 (enExample) |
| KR (1) | KR20210063351A (enExample) |
| CN (1) | CN111417655A (enExample) |
| AU (1) | AU2019327456A1 (enExample) |
| BR (1) | BR112021003843A2 (enExample) |
| CA (1) | CA3110647A1 (enExample) |
| IL (1) | IL281076A (enExample) |
| MX (1) | MX2021002301A (enExample) |
| SG (1) | SG11202101875VA (enExample) |
| WO (1) | WO2020047176A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002573A1 (en) * | 2015-11-03 | 2017-05-11 | Ambrx, Inc. | Anti-cd3 antibodies and their uses |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| WO2021173889A1 (en) * | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| AU2021333577B2 (en) | 2020-08-25 | 2025-09-11 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting HIV and methods of use |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| CN120344270A (zh) | 2022-10-07 | 2025-07-18 | Ambrx 公司 | 药物接头及其抗体缀合物 |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| FR2504010B1 (fr) | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4589071A (en) | 1982-04-19 | 1986-05-13 | Nissan Motor Co., Ltd. | Method and apparatus for controlling reduction ratio of continuously variable transmission with acceleration compensation |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| ATE159858T1 (de) | 1983-09-26 | 1997-11-15 | Ehrenfeld Udo | Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| US4659839A (en) | 1984-10-10 | 1987-04-21 | Mallinckrodt, Inc. | Coupling agents for radiolabeled antibody fragments |
| EP0188256B1 (en) | 1985-01-14 | 1991-08-21 | NeoRx | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| CN1269805A (zh) | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | 生长激素和相关蛋白的衍生物 |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| ATE365210T1 (de) | 1998-10-30 | 2007-07-15 | Novozymes As | Glykosylierte proteine mit reduzierter allergenität |
| US6479470B1 (en) | 1999-04-28 | 2002-11-12 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| WO2003101972A1 (en) | 2002-05-30 | 2003-12-11 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| HUE026914T2 (en) * | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| CA2561686C (en) | 2004-03-31 | 2014-12-02 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| EP1812031B1 (en) | 2004-11-01 | 2015-06-24 | The Regents of the University of California | Compositions and methods for modification of biomolecules |
| US7385028B2 (en) | 2004-12-22 | 2008-06-10 | Ambrx, Inc | Derivatization of non-natural amino acids and polypeptides |
| JP4616237B2 (ja) | 2006-11-07 | 2011-01-19 | 日本電信電話株式会社 | シリコン化合物薄膜の形成方法 |
| JP5773382B2 (ja) | 2010-12-29 | 2015-09-02 | 株式会社Sumco | シリカガラスルツボ及びその製造方法 |
| CN103717595A (zh) | 2011-05-27 | 2014-04-09 | Ambrx公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| EP4406612A3 (en) | 2012-06-19 | 2024-10-16 | Ambrx, Inc. | Anti-cd70 antibody drug conjugates |
| JP6501270B2 (ja) | 2013-03-14 | 2019-04-17 | ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ | 標的化剤抗体抱合体およびその使用 |
| SG10201913680PA (en) * | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
| PL3322727T3 (pl) * | 2015-07-15 | 2026-05-11 | Genmab A/S | Humanizowane lub chimeryczne przeciwciała cd3 |
| CA3002573A1 (en) | 2015-11-03 | 2017-05-11 | Ambrx, Inc. | Anti-cd3 antibodies and their uses |
| CN109069635B (zh) * | 2016-02-04 | 2023-09-26 | 斯克利普斯研究所 | 人源化抗cd3抗体、偶联物及其用途 |
-
2019
- 2019-08-28 KR KR1020217009160A patent/KR20210063351A/ko not_active Ceased
- 2019-08-28 AU AU2019327456A patent/AU2019327456A1/en not_active Abandoned
- 2019-08-28 WO PCT/US2019/048677 patent/WO2020047176A1/en not_active Ceased
- 2019-08-28 BR BR112021003843-4A patent/BR112021003843A2/pt unknown
- 2019-08-28 MX MX2021002301A patent/MX2021002301A/es unknown
- 2019-08-28 CN CN201980004962.5A patent/CN111417655A/zh active Pending
- 2019-08-28 US US17/272,241 patent/US12377294B2/en active Active
- 2019-08-28 JP JP2021510639A patent/JP7759805B2/ja active Active
- 2019-08-28 EP EP19773581.4A patent/EP3844188A1/en active Pending
- 2019-08-28 SG SG11202101875VA patent/SG11202101875VA/en unknown
- 2019-08-28 CA CA3110647A patent/CA3110647A1/en active Pending
-
2021
- 2021-02-24 IL IL281076A patent/IL281076A/en unknown
-
2025
- 2025-03-26 JP JP2025050991A patent/JP2025098156A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024123231A5 (enExample) | ||
| TWI250988B (en) | Thrombopoietic compounds | |
| US6177404B1 (en) | Conjugates useful in the treatment of benign prostatic hyperplasia | |
| IL273285B1 (en) | Anti- folate receptor alpha antibody conjugates and their uses | |
| CN108066772B (zh) | 靶向tacstd2的抗体与药物偶联体(adc)分子 | |
| CN110698565A (zh) | 靶向肿瘤的CD38-pHLIP融合肽 | |
| JP2012116864A (ja) | Ｇｌｐ−１化合物 | |
| JP2002543111A (ja) | ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅 | |
| JP6876618B2 (ja) | 治療目的のための抗体−ウレアーゼコンジュゲート | |
| CN115175917A (zh) | 药物缀合物及其应用 | |
| SK57399A3 (en) | Conjugates useful in the treatment of prostate cancer | |
| JP2022512746A5 (enExample) | ||
| CN115916801A (zh) | 新型的α螺旋双性细胞穿透肽及其用途 | |
| US20030232760A1 (en) | Conjugates useful in the treatment of prostate cancer | |
| CN109414509B (zh) | 使用双特异性抗体的抗体药物偶联物平台 | |
| US10441628B2 (en) | High activity tumour inhibitor and preparation method and use thereof | |
| JP6656661B2 (ja) | プレキシンの結合調節剤 | |
| AU7432196A (en) | Conjugates useful in the treatment of benign prostatic hyperplasia | |
| JP2023520498A (ja) | Ｇｌｐ－２誘導体またはその持続型結合体を含む放射線療法、化学療法、またはこれらの組合わせにより誘発された粘膜炎の予防または治療用薬学的組成物 | |
| US10526385B2 (en) | YAP protein inhibiting polypeptide and application thereof | |
| WO2014044793A2 (en) | Cd22-binding peptides | |
| US20210214399A1 (en) | Ph low insertion peptide and composition thereof | |
| CN113039194A (zh) | 具有免疫调节特性的肽 | |
| JP7179855B2 (ja) | 低ｐＨ挿入ペプチド及びその組成物 | |
| US6274704B1 (en) | Peptides derived from the heparin binding domain of fibronectin |